Model
|
No. (%) with access revision within 1 year
|
Hazard ratio (95 % CI) for loss of patency, SLE-attributed vs. other ESRD
|
---|
Unadjusted
|
Adjusted for demographics
|
Adjusted for demographics + clinical
|
---|
Primary analysis
| | | | |
SLE-attributed ESRD
|
21 (43.8 %)
|
0.70 (0.45-1.09)
|
0.81 (0.52-1.26)
|
0.88 (0.57-1.37)
|
Other ESRD
|
7,169 (55.0 %)
|
1.00 (ref.)
|
1.00 (ref.)
|
1.00 (ref.)
|
P
|
0.12
|
0.11
|
0.35
|
0.58
|
Excluding patients <18 years oldb
| | | | |
SLE-attributed ESRD
|
21 (43.8 %)
|
0.70 (0.45-1.08)
|
0.81 (0.52-1.26)
|
0.88 (0.57-1.37)
|
Other ESRD
|
7,165 (55.1 %)
|
1.00 (ref.)
|
1.00 (ref.)
|
1.00 (ref.)
|
P
|
0.12
|
0.11
|
0.35
|
0.57
|
Only among patients with Medicare at ESRD startc
| | | | |
SLE-attributed ESRD
|
---d
|
0.91 (0.55-1.52)
|
0.86 (0.52-1.42)
|
0.92 (0.55-1.53)
|
Other ESRD
|
1125 (13.0 %)
|
1.00 (ref.)
|
1.00 (ref.)
|
1.00 (ref.)
|
P
|
0.76
|
0.73
|
0.55
|
0.75
|
SLE and other GN compared to other ESRDe
| | | | |
SLE-attributed ESRD
|
---d
|
0.69 (0.44-1.07)
|
0.80 (0.52-1.24)
|
0.87 (0.56-1.35)
|
Other GN-attributed ESRD
|
60 (6.9 %)
|
0.79 (0.71-0.88)
|
0.87 (0.78-0.96)
|
0.91 (0.82-1.02)
|
Other ESRD
|
1433 (11.8 %)
|
1.00 (ref.)
|
1.00 (ref.)
|
1.00 (ref.)
|
P
|
<0.001
|
0.10/<0.001
|
0.32/0.008
|
0.54/0.09
|
Matched analysisf
| | | | |
SLE-attributed ESRD
|
21 (43.8 %)
|
0.71 (0.42-1.19)
|
0.70 (0.42-1.15)
|
0.81 (0.47-1.40)
|
Other ESRD
|
89 (58.2 %)
|
1.00 (ref.)
|
1.00 (ref.)
|
1.00 (ref.)
|
P
|
0.08
|
0.19
|
0.16
|
0.46
|
Events prior to 90 days included on day 91
| | | | |
SLE-attributed ESRD
|
21 (43.8 %)
|
0.73 (0.47-1.13)
|
0.81 (0.52-1.27)
|
0.88 (0.57-1.37)
|
Other ESRD
|
7,169 (55.0 %)
|
1.00 (ref.)
|
1.00 (ref.)
|
1.00 (ref.)
|
P
|
0.12
|
0.16
|
0.36
|
0.57
|
Events prior to 90 days excludedg
| | | | |
SLE-attributed ESRD
|
13 (32.5 %)
|
0.85 (0.49-1.46)
|
0.76 (0.44-1.31)
|
0.84 (0.48-1.45)
|
Other ESRD
|
3,377 (36.6 %)
|
1.00 (ref.)
|
1.00 (ref.)
|
1.00 (ref.)
|
P
|
0.59
|
0.56
|
0.32
|
0.52
|
- AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, GN glomerulonephritis, SLE systemic lupus eythematosus. Demographics: age (continuous), sex, race; clinical: body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
- aDefined as a revision or placement of a new AVF, AVG, or catheter (see Table 1)
- bExcluding n = 14 patients (4 SLE, 10 other) who were <18 years old
- cExcluding n = 4,375 patients (23 SLE, 4,352 other) without Medicare at ESRD start
- dNot reportable due to cell size < 10
- eOther GN included 864 patients with CMS-2728 ICD-9 codes for attributed cause of glomerulonephritis (582.9, 582.1, 583.1, 583.21, 583.22, 583.81, 583.82, 583.4, 580.0, and 582.0) or secondary glomerulonephritis/vasculitis (excluding SLE-ESRD; 287.0, 710.1, 283.11, 446.0, 446.4, 583.92, 446.20, 446.21, and 583.91)
- fAmong n = 201 patients, including 48 SLE patients and 153 matched non-SLE patients, using 2:1 matching on age group (<30, 30–49, and >50 years), sex (female and male), and race (black and not black). Models stratified on matching variable to account for matching
- gExcluding n = 3,801 patients (35 SLE, 8,456 other) with follow-up time <90 days